One thing is certain about cancer treatment: The active ingredient must achieve high concentrations in the brain – without causing unacceptable toxicity in the patient. That’s an especially tricky balance to achieve in treating gliomas and glioblastomas; that’s because the treatment compound must cross the blood brain barrier to reach the tumor target; otherwise patient survival rates won’t rise. But when that happens, neurotoxicity may follow.
That’s why any advance in brain-penetrating drugs with reduced toxicity is welcome news in the cancer research community, and that’s why so many key opinion leaders find themselves increasingly excited about carboxyamidotriazole orotate (CTO), the second-generation, “new and improved” version of 5-amino-1-(4- (4-chlorobenzoyl)-3,5-dichlorobenzyl)-1,2,3-triazole-4-carboxamide, known from more than a dozen clinical trials in the 1990s as CAI.
Read the full feature here: BioWorld’s Partner in Focus: Tactical Therapeutics